Brian Cheng
Stock Analyst at JP Morgan
(1.16)
# 3,461
Out of 4,711 analysts
58
Total ratings
36.17%
Success rate
-16.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brian Cheng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EDIT Editas Medicine | Downgrades: Underweight | n/a | $1.31 | - | 3 | Dec 16, 2024 | |
| ZYME Zymeworks | Upgrades: Overweight | $18 | $14.14 | +27.30% | 2 | Dec 16, 2024 | |
| BPMC Blueprint Medicines | Initiates: Overweight | $126 | $90.14 | +39.78% | 1 | Nov 14, 2024 | |
| XNCR Xencor | Maintains: Overweight | $27 → $28 | $24.13 | +16.04% | 4 | Nov 7, 2024 | |
| ITOS iTeos Therapeutics | Maintains: Overweight | $27 → $24 | $7.42 | +223.45% | 2 | Aug 12, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $61 → $55 | $12.18 | +351.56% | 3 | Aug 12, 2024 | |
| IMVT Immunovant | Maintains: Overweight | $51 → $46 | $25.86 | +77.88% | 2 | Aug 8, 2024 | |
| KYTX Kyverna Therapeutics | Maintains: Overweight | $39 → $33 | $4.00 | +725.00% | 2 | Jul 31, 2024 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $39 → $48 | $41.49 | +15.69% | 3 | Jul 25, 2024 | |
| MGX Metagenomi | Downgrades: Neutral | $16 → $6 | $4.05 | +48.15% | 2 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $10.97 | +118.78% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.76 | - | 2 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $5 | $1.60 | +212.50% | 3 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $8 | $1.87 | +327.81% | 3 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $14.90 | +54.36% | 1 | Dec 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $15 | $11.57 | +29.65% | 6 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $14 | $0.69 | +1,922.24% | 3 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $1.96 | - | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $0.91 | +559.34% | 2 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $3.97 | - | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.84 | - | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $9.45 | +153.97% | 1 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.59 | +1,157.86% | 2 | Sep 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $85 | $15.48 | +449.10% | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $21 | $7.57 | +177.41% | 1 | Aug 3, 2021 |
Editas Medicine
Dec 16, 2024
Downgrades: Underweight
Price Target: n/a
Current: $1.31
Upside: -
Zymeworks
Dec 16, 2024
Upgrades: Overweight
Price Target: $18
Current: $14.14
Upside: +27.30%
Blueprint Medicines
Nov 14, 2024
Initiates: Overweight
Price Target: $126
Current: $90.14
Upside: +39.78%
Xencor
Nov 7, 2024
Maintains: Overweight
Price Target: $27 → $28
Current: $24.13
Upside: +16.04%
iTeos Therapeutics
Aug 12, 2024
Maintains: Overweight
Price Target: $27 → $24
Current: $7.42
Upside: +223.45%
Intellia Therapeutics
Aug 12, 2024
Maintains: Overweight
Price Target: $61 → $55
Current: $12.18
Upside: +351.56%
Immunovant
Aug 8, 2024
Maintains: Overweight
Price Target: $51 → $46
Current: $25.86
Upside: +77.88%
Kyverna Therapeutics
Jul 31, 2024
Maintains: Overweight
Price Target: $39 → $33
Current: $4.00
Upside: +725.00%
Protagonist Therapeutics
Jul 25, 2024
Maintains: Overweight
Price Target: $39 → $48
Current: $41.49
Upside: +15.69%
Metagenomi
May 2, 2024
Downgrades: Neutral
Price Target: $16 → $6
Current: $4.05
Upside: +48.15%
Apr 30, 2024
Initiates: Overweight
Price Target: $24
Current: $10.97
Upside: +118.78%
Mar 22, 2024
Downgrades: Underweight
Price Target: n/a
Current: $0.76
Upside: -
Mar 19, 2024
Upgrades: Neutral
Price Target: $5
Current: $1.60
Upside: +212.50%
Feb 27, 2024
Maintains: Overweight
Price Target: $9 → $8
Current: $1.87
Upside: +327.81%
Dec 5, 2023
Initiates: Overweight
Price Target: $23
Current: $14.90
Upside: +54.36%
Nov 14, 2023
Maintains: Overweight
Price Target: $16 → $15
Current: $11.57
Upside: +29.65%
Sep 25, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $0.69
Upside: +1,922.24%
Aug 10, 2023
Upgrades: Neutral
Price Target: n/a
Current: $1.96
Upside: -
Jun 1, 2023
Downgrades: Neutral
Price Target: $20 → $6
Current: $0.91
Upside: +559.34%
Dec 16, 2022
Initiates: Neutral
Price Target: n/a
Current: $3.97
Upside: -
Dec 7, 2022
Downgrades: Underweight
Price Target: n/a
Current: $0.84
Upside: -
Jan 7, 2022
Initiates: Overweight
Price Target: $24
Current: $9.45
Upside: +153.97%
Sep 2, 2021
Initiates: Overweight
Price Target: $20
Current: $1.59
Upside: +1,157.86%
Aug 10, 2021
Maintains: Overweight
Price Target: $71 → $85
Current: $15.48
Upside: +449.10%
Aug 3, 2021
Initiates: Overweight
Price Target: $21
Current: $7.57
Upside: +177.41%